Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44

Yu Hua Quan, Byungji Kim, Ji Ho Park, Yeonho Choi, Young Ho Choi, Hyun Koo Kim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). In order to enhance the therapeutic properties and reduce side effects, enormous efforts have been devoted to direct anticancer agents specifically to tumor tissues by the use of nanoparticles, or cancer cell marker attached drugs. However, cell-specific chemotherapy is still in its infancy and is not applicable to all types of cancers due to the complexity of the cancer occurrence and progress. In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. In proliferation experiments, HA-conjugated cisplatin showed dramatic cell viability decreases (from 100% to 42.31%) in H1299 cells, which overexpress CD44, whereas no such change was observed in A549 and HFL1, which have little to no expression of CD44. More importantly, conjugation with HA decreased the dosage concentration of cisplatin by 50-fold for both cytotoxic and anti-metastatic effects. In addition, HA-cisplatin conjugate treatment selectively decreased migration (from 100% to 7.8%) and invasiveness (from 100% to 21.4%, respectively) of H1299. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.

Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalExperimental Lung Research
Volume40
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Hyaluronic Acid
Non-Small Cell Lung Carcinoma
Cisplatin
Cells
Chemotherapy
Antineoplastic Agents
Neoplasms
Drug Therapy
Therapeutic Uses
Nanoparticles
Tumors
Cell Survival
Therapeutics
Tissue
Ligands
Membranes
Pharmaceutical Preparations
Experiments

Cite this

Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. / Quan, Yu Hua; Kim, Byungji; Park, Ji Ho; Choi, Yeonho; Choi, Young Ho; Kim, Hyun Koo .

In: Experimental Lung Research, Vol. 40, No. 10, 01.01.2014, p. 475-484.

Research output: Contribution to journalArticle

@article{0dab0dd30bb34c54920405250777758a,
title = "Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44",
abstract = "In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). In order to enhance the therapeutic properties and reduce side effects, enormous efforts have been devoted to direct anticancer agents specifically to tumor tissues by the use of nanoparticles, or cancer cell marker attached drugs. However, cell-specific chemotherapy is still in its infancy and is not applicable to all types of cancers due to the complexity of the cancer occurrence and progress. In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. In proliferation experiments, HA-conjugated cisplatin showed dramatic cell viability decreases (from 100{\%} to 42.31{\%}) in H1299 cells, which overexpress CD44, whereas no such change was observed in A549 and HFL1, which have little to no expression of CD44. More importantly, conjugation with HA decreased the dosage concentration of cisplatin by 50-fold for both cytotoxic and anti-metastatic effects. In addition, HA-cisplatin conjugate treatment selectively decreased migration (from 100{\%} to 7.8{\%}) and invasiveness (from 100{\%} to 21.4{\%}, respectively) of H1299. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.",
keywords = "CD44, Hyaluronan-cisplatin conjugate, Lung cancer",
author = "Quan, {Yu Hua} and Byungji Kim and Park, {Ji Ho} and Yeonho Choi and Choi, {Young Ho} and Kim, {Hyun Koo}",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/01902148.2014.905656",
language = "English",
volume = "40",
pages = "475--484",
journal = "Experimental Lung Research",
issn = "0190-2148",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44

AU - Quan, Yu Hua

AU - Kim, Byungji

AU - Park, Ji Ho

AU - Choi, Yeonho

AU - Choi, Young Ho

AU - Kim, Hyun Koo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). In order to enhance the therapeutic properties and reduce side effects, enormous efforts have been devoted to direct anticancer agents specifically to tumor tissues by the use of nanoparticles, or cancer cell marker attached drugs. However, cell-specific chemotherapy is still in its infancy and is not applicable to all types of cancers due to the complexity of the cancer occurrence and progress. In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. In proliferation experiments, HA-conjugated cisplatin showed dramatic cell viability decreases (from 100% to 42.31%) in H1299 cells, which overexpress CD44, whereas no such change was observed in A549 and HFL1, which have little to no expression of CD44. More importantly, conjugation with HA decreased the dosage concentration of cisplatin by 50-fold for both cytotoxic and anti-metastatic effects. In addition, HA-cisplatin conjugate treatment selectively decreased migration (from 100% to 7.8%) and invasiveness (from 100% to 21.4%, respectively) of H1299. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.

AB - In spite of severe side effects, chemotherapy is widely used as a major anticancer treatment in non-small cell lung cancer (NSCLC). In order to enhance the therapeutic properties and reduce side effects, enormous efforts have been devoted to direct anticancer agents specifically to tumor tissues by the use of nanoparticles, or cancer cell marker attached drugs. However, cell-specific chemotherapy is still in its infancy and is not applicable to all types of cancers due to the complexity of the cancer occurrence and progress. In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. In proliferation experiments, HA-conjugated cisplatin showed dramatic cell viability decreases (from 100% to 42.31%) in H1299 cells, which overexpress CD44, whereas no such change was observed in A549 and HFL1, which have little to no expression of CD44. More importantly, conjugation with HA decreased the dosage concentration of cisplatin by 50-fold for both cytotoxic and anti-metastatic effects. In addition, HA-cisplatin conjugate treatment selectively decreased migration (from 100% to 7.8%) and invasiveness (from 100% to 21.4%, respectively) of H1299. Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties.

KW - CD44

KW - Hyaluronan-cisplatin conjugate

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84908597322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908597322&partnerID=8YFLogxK

U2 - 10.3109/01902148.2014.905656

DO - 10.3109/01902148.2014.905656

M3 - Article

C2 - 25299431

AN - SCOPUS:84908597322

VL - 40

SP - 475

EP - 484

JO - Experimental Lung Research

JF - Experimental Lung Research

SN - 0190-2148

IS - 10

ER -